【Conference Information】2014 Asia Pacific Biotech Investment Forum: Bio-investment Strategy in Asia
Microbio announced today that it has received TFDA new drug approval for “Herbiron Oral Solution”
China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC) and Microbio Group Collaborate on New Drug Development
Microbio receives Macao Import Drug License Approval for Chemo Young
Microbio announced today that it has signed a global exclusive license with the National Health Research Institutes (NHRI) for a novel molecule treating Hepatitis C infection
MICROBIO receives TFDA New Drug Administration (NDA) Approval for Herbiron
Microbio receives TFDA New Drug Administration (NDA) Approval for Herbiron for the treatment of primary dysmenorrhea and iron-deficiency anemia
Microbio received the approval from TFDA to initiate the MB-6 Phase III clinical trial
Chemo Young Oral Solution obtained the R.O.C and Japan patents for inventions
